# OnCo record sacituzumab-govitecan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sacituzumab-govitecan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sacituzumab-govitecan" ;
  schema:name "Sacituzumab govitecan"@en ;
  schema:description "Sacituzumab govitecan carries chemotherapy to cancer cells bearing TROP2. It is FDA-approved for specific advanced breast-cancer settings, including two first-line triple-negative indications."@en ;
  schema:url <https://onco.cc/drugs/sacituzumab-govitecan/> ;
  schema:dateModified "2026-10-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Sacituzumab_govitecan> ;
  owl:sameAs <http://www.wikidata.org/entity/Q23901469> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-hr-positive-breast-cancer>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sacituzumab%20govitecan>, <https://www.nice.org.uk/guidance/ta819>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22TRODELVY%22>, <https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Trodelvy" ;
  onco:approval "EU 2021: mTNBC ≥2 lines; HR+ 2023", "US 2021: Adults with unresectable locally advanced or metastatic TNBC after at least two prior systemic therapies, including at least one for metastatic disease", "US 2023: Adults with unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer after endocrine-based therapy and at least two additional systemic therapies in the metastatic setting", "US 2026: First-line adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based therapy; monotherapy", "US 2026: First-line adults with unresectable locally advanced or metastatic TNBC, PD-L1 CPS at least 10 by an FDA-authorized test, with pembrolizumab or pembrolizumab/berahyaluronidase alfa", "EU 2021: Unresectable or metastatic TNBC after two or more systemic therapies, at least one for advanced disease (ASCENT); marketing authorisation issued 22 November 2021", "EU 2026: First-line unresectable locally advanced or metastatic TNBC in patients who are not candidates for PD-1 or PD-L1 inhibitor therapy (ASCENT-03); listed in the EMA therapeutic indications read on 24 September 2026", "UK 2022: Unresectable triple-negative locally advanced or metastatic breast cancer after two or more systemic therapies, at least one for advanced disease; NICE TA819 (17 August 2022) recommends within the marketing authorisation with a commercial arrangement" ;
  onco:acceleratedApproval "US 2020-04-22: Adults with metastatic TNBC following at least 2 prior therapies for metastatic disease", "US 2021-04-13: Treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor" ;
  onco:acceleratedApprovalConfirmed "US 2021-04-07: Adults with metastatic TNBC following at least 2 prior therapies for metastatic disease" ;
  onco:related <https://onco.cc/biomarkers/pd-l1-cps/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/trop2/> ;
  onco:companies <https://onco.cc/companies/gilead/> ;
  onco:terms <https://onco.cc/terms/bystander-effect/>, <https://onco.cc/terms/payload/>, <https://onco.cc/terms/cl2a/> ;
  onco:trials <https://onco.cc/trials/ascent/>, <https://onco.cc/trials/ascent-03/>, <https://onco.cc/trials/ascent-04/>, <https://onco.cc/trials/nct05089734/>, <https://onco.cc/trials/nct06801834/>, <https://onco.cc/trials/nct06486441/>, <https://onco.cc/trials/nct05633667/>, <https://onco.cc/trials/nct05186974/>, <https://onco.cc/trials/nct06926920/>, <https://onco.cc/trials/nct03547973/>, <https://onco.cc/trials/nct05840211/>, <https://onco.cc/trials/nct05119907/>, <https://onco.cc/trials/nct05609968/>, <https://onco.cc/trials/nct05101096/>, <https://onco.cc/trials/nct04454437/>, <https://onco.cc/trials/nct03964727/>, <https://onco.cc/trials/nct04639986/>, <https://onco.cc/trials/nct05327530/>, <https://onco.cc/trials/nct06827613/>, <https://onco.cc/trials/diamond/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/>, <https://onco.cc/key-papers/paper-keynote-355-nejm-2022/> .